Isogenica's key management team brings substantial scientific, commercial, financial, legal and business administration experience and expertise to the company.

		Kevin Matthews MA, D.Phil, CChem, CSi, MACS CEO Kevin joined Isogenica in October 2009, prior to which he was CEO of Oxonica plc (2001-2009), one of the UK's leading nanotechnology businesses. Kevin is also a non-executive director and chairman of the remuneration committee of Elementis plc, a UK FTSE listed international speciality chemicals business. He is also chairman of the UK's Nanotechnology Knowledge Transfer Network. Kevin has a DPhil in chemistry from Oxford and after an initial spell in research has spent his career taking new technologies to market. In the process he has become very familiar with the challenges of financing, technology development and protection, and commercialisation of new products both through direct sales and licensing across a broad range of industries including pharmaceutical, biotech, medical diagnostics, cosmetics and industrial materials.
		Chris Ullman PhD CSO Chris joined Isogenica in 2002 and since then has been heavily involved in the development of the company's CIS display technology. Prior to joining Isogenica, Chris was Team Leader for Gendaq Ltd. (later acquired by Sangamo Biosciences Inc.), developing customised transcription factors. The company was spun-out from Sir Aaron Klug's Laboratory at the LMB, Cambridge.
		Anthony M. Nixon MA (Cantab), FCIArb, DipICArb, FLS General Counsel Anthony brings over twenty years' senior management experience to Isogenica. He is a practising Barrister, having been called to the Bar in 1979, and has held a number of in-house legal positions including Vice President Operations and Legal Affairs and Company Secretary at the newly formed Cambridge Antibody Technology, where he took the company from start-up to a full listing on the London Stock Exchange.
		Neil Cooley PhD Alliance Manager Joining Isogenica in 2005, Neil brought with him around 20 years of molecular biology experience gained in the application and development of enabling technologies for the AgChem and biotech industries. Following research at the University and Birmingham where he published a number of scientific papers, Neil moved to AgrEvo UK Ltd where he directed the skills he had gained to develop molecular methodologies for the identification, validation and exploitation of fungicide targets in phytopathogenic fungi. Neil moved into biotech in 2001 when he joined Discerna Ltd, a spin out from the Babraham Institute utilising ribosome display technology to discover single chain antibodies. After joining Isogenica as Senior Scientist, Neil is now responsible for overseeing and directing Isogenica's external projects in the role of Alliances Manager.
		Ambili Nair PhD Business Development Ambili joined the Isogenica team in January 2010. She started her working career as a Biotechnologist in Malaysia, with Sime Darby. She then left for the UK to pursue an MPhil in Genetics and a PhD in Plant Sciences at the University of Cambridge. Following this, she worked as a Postdoctoral Research Fellow at the Max-Planck Institute for Plant Breeding (Cologne) and at the Department of Molecular Biology, University of Bonn, Germany. She left academia to work as a Project Manager for a bio-business development consultancy in Cambridge which helped biotech and life science companies overcome barriers to commercialisation. There she gained broad experience in business analysis, technology strategies, product and technology transfer as well as market research and analysis. Immediately before joining Isogenica, Ambili worked for a healthcare and biotech consultancy. She has broad experience in business development, project management, market assessment, strategic reviews, M&A, licensing & negotiations, scientific & commercial due diligence, litigation support, evaluating distribution channels, and trend analysis.